MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING

By
Justin.choi
-
0
130
Scientists examined 81 lung cancer patients under immune checkpoint blockade (ICB) treatment and found that patients with MET amplification were resistant to ICB and had a poor progress-free survival.
[Cancer Discovery]
Zhang, Y., Yang, Q., Zeng, X., Wang, M., Dong, S., Yang, B., Tu, X., Wei, T., Xie, W., Zhang, C., Guo, Q., Kloeber, J. A., Cao, Y., Guo, G., Zhou, Q., Zhao, F., Huang, J., Liu, L., Zhang, K., … Lou, Z. (2021). MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING. Cancer Discovery. https://doi.org/10.1158/2159-8290.CD-20-1500 Cite
Abstract